Tiverton Asset Management’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Tiverton Asset Management’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-128,926	Closed	-$758K	–	198
2016 Q3	$758K	Sell	128,926 -319,032	-71%	-$1.12M	0.06%	143
2016 Q2	$10M	Buy	447,958 +219,490	+96%	+$901K	0.42%	75
2016 Q1	$1.23M	Sell	228,468 -21,532	-9%	-$136K	0.04%	147
2015 Q4	$2.97M	Sell	250,000 -50,000	-17%	-$572K	0.09%	127
2015 Q3	$2.46M	Hold	300,000	–	–	0.05%	143
2015 Q2	$4.18M	Hold	300,000	–	–	0.08%	137
2015 Q1	$7.21M	Hold	300,000	–	–	0.15%	115
2014 Q4	$4.94M	Hold	300,000	–	–	0.1%	115
2014 Q3	$3.82M	Buy	300,000 +260,000	+650%	+$3.92M	0.09%	115
2014 Q2	$903K	Hold	40,000	–	–	0.02%	122
2014 Q1	$1.13M	Buy	+40,000	New	+$1.49M	0.02%	117

Other funds holding DRNA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Tiverton Asset Management's DRNA Position: Q4 2016 in Review

Tiverton Asset Management sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2016, closing a stake of 128,926 shares — an estimated $758K sold.

Tiverton Asset Management first reported a position in DRNA in Q1 2014 and held it in 11 quarters. The position peaked at $10M in Q2 2016. 50 funds tracked by Wall St. Rank hold DRNA as of Q4 2016.

Tiverton Asset Management reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2016 after selling out during the quarter.
Tiverton Asset Management sold 128,926 Dicerna Pharmaceuticals, Inc. shares in Q4 2016, an estimated $758K.
Tiverton Asset Management first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2014 and held it in 11 quarters.
Tiverton Asset Management's Dicerna Pharmaceuticals, Inc. position peaked at $10M in Q2 2016.
50 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2016.

Based on Tiverton Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.